A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

Parkinson's Disease Psychosis Clinical Trial

Official title:
A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of 40 mg pimavanserin compared to placebo in patients with Parkinson's disease psychosis (PDP).

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01174004
Study type	Interventional
Source	ACADIA Pharmaceuticals Inc.
Contact
Status	Completed
Phase	Phase 3
Start date	July 2010
Completion date	November 2012

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06068465` - A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis	Phase 3
Recruiting	`NCT04373317` - Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis	Phase 4
Completed	`NCT01518309` - An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients	Phase 2
Completed	`NCT00658567` - A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis	Phase 3
Completed	`NCT00477672` - A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis	Phase 3
Completed	`NCT00550238` - A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis	Phase 3
Recruiting	`NCT05590637` - Comparing Antipsychotic Medications in LBD Over Time	Phase 4
Approved for marketing	`NCT02762591` - Expanded Access of Pimavanserin for Patients With PD Psychosis	N/A